Transthyretin amyloid cardiomyopathy (ATTR-CM)
- Confirm TTR amyloid and exclude AL amyloidosis
- TTR stabilizer slows disease progression
- Tafamidis/acoramidis are oral stabilizer options
- RNA-silencing therapy may apply by phenotype/approval
- Diuretics manage congestion cautiously
- Diagnose early—lost myocardium is not restored
Use at a glance
- Confirm TTR amyloid and exclude AL amyloidosis
Practical pearls
- TTR stabilizer slows disease progression
- Tafamidis/acoramidis are oral stabilizer options
Choosing treatment
- RNA-silencing therapy may apply by phenotype/approval
- Diagnose early—lost myocardium is not restored
Other practical pearls
- Diuretics manage congestion cautiously
Self-check
- What must be distinguished before ATTR-CM treatment?
TTR amyloid from AL amyloidosis. - Does ATTR-CM treatment restore lost myocardium?
No.
Drugs used for this (3)
All clinical uses · Open Transthyretin amyloid cardiomyopathy (ATTR-CM) in the interactive console ↗